Suppr超能文献

用于结直肠癌诊断的循环和粪便核酸分析。

Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

作者信息

De Maio Giulia, Rengucci Claudia, Zoli Wainer, Calistri Daniele

机构信息

Giulia De Maio, Claudia Rengucci, Wainer Zoli, Daniele Calistri, Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Via Piero Maroncelli, 40-47014 Meldola, Italy.

出版信息

World J Gastroenterol. 2014 Jan 28;20(4):957-67. doi: 10.3748/wjg.v20.i4.957.

Abstract

In recent years, the need to identify molecular markers characterized by high sensitivity and specificity in detecting and monitoring early and colorectal cancer lesions has increased. Up to now, none of the markers or panels of markers analyzed have met the rigorous standards required of a screening program. The important discovery of circulating nucleic acids in biological fluids has aroused intense scientific interest because of their usefulness in malignant and non malignant diseases. Over time, their yield and stability have been identified and compared with other "standard" biomarkers. The analysis of circulating DNA from blood and stool is a relatively simple and non-invasive procedure, representing a very attractive marker to detect genetic and epigenetic mutations and to monitor disease progression. A correlation between blood and stool biomarkers could also help to enhance currently available diagnostic approaches. However, various processing and analytic problems need to be resolved before such an approach can be applied in clinical practice.

摘要

近年来,在检测和监测早期结直肠癌病变方面,识别具有高灵敏度和特异性的分子标志物的需求不断增加。到目前为止,所分析的任何一种标志物或标志物组合都未达到筛查计划所需的严格标准。生物体液中循环核酸的重要发现因其在恶性和非恶性疾病中的用途而引起了强烈的科学兴趣。随着时间的推移,它们的产量和稳定性已被确定,并与其他“标准”生物标志物进行了比较。对血液和粪便中循环DNA的分析是一种相对简单且非侵入性的程序,是检测基因和表观遗传突变以及监测疾病进展的极具吸引力的标志物。血液和粪便生物标志物之间的相关性也有助于加强目前可用的诊断方法。然而,在这种方法应用于临床实践之前,需要解决各种处理和分析问题。

相似文献

1
Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.
World J Gastroenterol. 2014 Jan 28;20(4):957-67. doi: 10.3748/wjg.v20.i4.957.
2
Molecular detection of colorectal neoplasia.
Gastroenterology. 2010 Jun;138(6):2127-39. doi: 10.1053/j.gastro.2010.01.055.
3
Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
Clin Chim Acta. 2016 Apr 1;455:26-32. doi: 10.1016/j.cca.2016.01.016. Epub 2016 Jan 18.
4
Stool DNA methylation assays in colorectal cancer screening.
World J Gastroenterol. 2015 Sep 21;21(35):10057-61. doi: 10.3748/wjg.v21.i35.10057.
5
Circulating Non-coding RNA as Biomarkers in Colorectal Cancer.
Adv Exp Med Biol. 2016;937:171-81. doi: 10.1007/978-3-319-42059-2_9.
6
Colorectal cancer: from prevention to personalized medicine.
World J Gastroenterol. 2014 Jun 14;20(22):6786-808. doi: 10.3748/wjg.v20.i22.6786.
8
Circulating free DNA in a screening program for early colorectal cancer detection.
Tumori. 2014 Mar-Apr;100(2):115-21. doi: 10.1177/030089161410000201.
9
A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population.
J Cancer Res Clin Oncol. 2019 Oct;145(10):2423-2432. doi: 10.1007/s00432-019-02992-2. Epub 2019 Aug 27.

引用本文的文献

1
Importance of Extracellular Vesicle Derived RNAs as Critical Colorectal Cancer Biomarkers.
ACS Bio Med Chem Au. 2022 Mar 1;2(3):222-235. doi: 10.1021/acsbiomedchemau.1c00043. eCollection 2022 Jun 15.
2
Computational Simulation of Colorectal Cancer Biomarker Particle Mobility in a 3D Model.
Molecules. 2023 Jan 6;28(2):589. doi: 10.3390/molecules28020589.
3
Combined Efficacy of CXCL5, STC2, and CHI3L1 in the Diagnosis of Colorectal Cancer.
J Oncol. 2022 May 20;2022:7271514. doi: 10.1155/2022/7271514. eCollection 2022.
4
Superiority of fecal carcinoembryonic antigen as diagnosis marker for adenomatous polyposis coli and asymptomatic colorectal cancer.
Therap Adv Gastroenterol. 2021 Dec 21;14:17562848211062792. doi: 10.1177/17562848211062792. eCollection 2021.
5
Extracellular vesicles: General features and usefulness in diagnosis and therapeutic management of colorectal cancer.
World J Gastrointest Oncol. 2021 Nov 15;13(11):1561-1598. doi: 10.4251/wjgo.v13.i11.1561.
6
Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges.
Cancers (Basel). 2021 Apr 14;13(8):1874. doi: 10.3390/cancers13081874.
7
Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA.
Curr Treat Options Oncol. 2021 Feb 8;22(3):21. doi: 10.1007/s11864-021-00821-8.

本文引用的文献

2
Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology.
Onco Targets Ther. 2013 Jul 8;6:819-32. doi: 10.2147/OTT.S44668. Print 2013.
4
Circulating cell-free DNA in serum as a biomarker of colorectal cancer.
J Clin Pathol. 2013 Sep;66(9):775-8. doi: 10.1136/jclinpath-2013-201521. Epub 2013 Jul 6.
5
Fecal molecular markers for colorectal cancer screening.
Gastroenterol Res Pract. 2012;2012:184343. doi: 10.1155/2012/184343. Epub 2011 Nov 17.
6
8
Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.
Gastroenterology. 2012 Feb;142(2):248-56; quiz e25-6. doi: 10.1053/j.gastro.2011.10.031. Epub 2011 Nov 4.
9
The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.
Clin Gastroenterol Hepatol. 2012 Mar;10(3):272-7.e1. doi: 10.1016/j.cgh.2011.10.008. Epub 2011 Oct 20.
10
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.
Br J Cancer. 2011 Jul 12;105(2):239-45. doi: 10.1038/bjc.2011.230. Epub 2011 Jun 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验